DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the INDEGENE LIMITED (INDGN) share price today?

INDEGENE LIMITED (INDGN) is trading at ₹510.9 on the NSE, down 0.01% on the day. Source: DocStoX.

What is the PE ratio of INDEGENE LIMITED?

INDEGENE LIMITED has a price-to-earnings (PE) ratio of 30.7 in the Healthcare sector.

What is the market capitalisation of INDEGENE LIMITED?

INDEGENE LIMITED has a market capitalisation of approximately ₹12,308 crore.

INDEGENE LIMITED

INDGN·NSE·Healthcare

₹510.90▼ -0.05 (-0.01%)

Healthcare · Healthcare Technology

A steady, established business

NIFTY 500NIFTY SMALLCAP 250

Day₹504.95

₹515.50

52W₹414

₹59753%

Open

₹515.50

High

₹515.50

Low

₹504.95

Prev Close

₹510.95

Volume

1.16L

VWAP

₹509.45

Snapshot

Key fundamentals

Market Cap

₹12,308 Cr

P/E Ratio

30.68Fair

P/B Ratio

3.96

EPS

₹16.65

Book Value

₹130.00

ROE

14.40%Average

ROCE

19.00%Efficient

Dividend Yield

0.40%

Debt / Equity

0.05Low

Face Value

₹2.00

52W High

₹596.80

52W Low

₹414.00

Sector

Healthcare

Industry

Healthcare Technology

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹163

▼ 68.1%downside

Trading at ₹511 — 68% above our estimate

BearFair valueBull

₹139₹163₹221

/100

Business quality — Solid

Growth 59Profitability 50Efficiency 28Valuation 73

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Revenue compounding 15% over 3 years

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

14% ROE fading to 12% over ~10 yrs, on ₹130 book

₹147

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹221

Analyst target

No analyst coverage

—

Blended fair value₹163

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Revenue compounding 15% over 3 years

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

30.7Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

14.4%Average

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.05Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹12,308 Cr

P/B

3.96

EPS

₹16.65

Div Yield

0.40%

What changed

Recent changes

Foreign investors-0.3% stake last quarter
Domestic institutions+0.5% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 30.7×

Growth

Strong

+15% rev CAGR

Profitability

Healthy

14.4% ROE

Financial health

Rock solid

D/E 0.05

Momentum

N/A

No technicals

Today

Trading activity

Delivery %63.8%

Turnover₹590.78L Cr

Trades9,157

VWAP₹509.45

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.0%

+29.4%

10Y

—

Profit

+14.7%

+21.9%

10Y

—

EPS

+11.6%

-55.5%

10Y

—

Profile

Pros

Company is almost debt free.

Watch-outs

Cons

Working capital days have increased from 61.8 days to 120 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 0.35 pts; domestic institutions added 0.45 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

Promoter

Public

81.3%-0.09

FII / FPI

9.9%-0.35

DII

8.7%+0.45

Quarterly trend

Ownership over time

Q1 FY27

FII9.92%

DII8.74%

Public81.34%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations[1]